Aaron Seth Rosenberg, MD, MS, discusses the emerging role of minimal residual disease to guide treatment decisions in multiple myeloma.
Aaron Seth Rosenberg, MD, MS
Advertisement
Articles by Aaron Seth Rosenberg, MD, MS
Aaron Seth Rosenberg, MD, MS, discusses the potential clinical implications of the phase 2 GRIFFIN trial in multiple myeloma.
Advertisement
Latest Updated Articles
Dr. Rosenberg on the Potential Clinical Implications of the GRIFFIN Trial in Multiple MyelomaPublished: July 27th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5